Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)

Brief description of study

The purpose of this research study is to explore the safety and efficacy of a drug called empagliflozin (EMPA) in reducing kidney and cardiovascular events in patients on maintenance hemodialysis (HD).

Clinical Study Identifier: s22-01497
Principal Investigator: David Michael Charytan.
Other Investigator: Qandeel Haq Soomro.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.